Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT02627820
Other study ID # 2015-P001574
Secondary ID
Status Withdrawn
Phase Phase 2
First received November 19, 2015
Last updated August 9, 2016
Start date January 2016
Est. completion date December 2018

Study information

Verified date January 2016
Source Brigham and Women's Hospital
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

ATTRwt (also known as senile systemic, or senile cardiac amyloidosis) is a progressive heart disease, causing congestive heart failure. It is caused by amyloid protein deposits in the heart, that are derived from a normal protein, TTR, made in the liver. The aim of the study is to determine whether lowering the blood levels of TTR, by a weekly injection of a compound designed specifically to do this, will slow the progression of the disease when treated patients are compared to previously-followed patients who were not receiving this drug. The study also aims to determine how well this drug is tolerated and the existence and severity of any drug side-effects.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date December 2018
Est. primary completion date December 2018
Accepts healthy volunteers No
Gender Both
Age group 50 Years to 90 Years
Eligibility All patients with documented SSA will be considered for inclusion. SSA is defined as an echocardiographic appearance of left ventricular wall thickness of 13 mm or more, in the absence of uncontrolled hypertension, and with a positive biopsy for amyloid, which also stains positive for TTR by immunochemistry or mass spectrometry. For the definition of SSA, genetic testing should be negative for a mutation. Identification of amyloid type is standard of care for all patients seen at the Cardiac Amyloidosis Program and the presence of a clinically -obtained positive biopsy will be a requirement for study inclusion. The positive biopsy can be from any organ, providing that the echocardiographic appearance is typical of amyloidosis.

Inclusion Criteria:

1. Patients should, in the opinion of the Investigator, be in a stable state in terms of NYHA class. Class I-III patients will be recruited.

2. Age 50-90 years

3. Male or non-pregnant, non-lactating females. If a woman is premenopausal, or a male partners with a premenopausal woman, she/he must be willing to use the following methods of contraception: condoms, oral/hormonal contraception, Intrauterine Device, diaphragm, or abstinence

4. Written informed consent to be obtained prior to study treatment

5. Histochemical diagnosis of amyloidosis as based on detection by polarizing microscopy of green birefringent material in Congo red-stained tissue specimens

6. Molecular definition of the absence of a TTR mutation or immunohistochemical staining of amyloid fibrils with anti TTR antibody and negative genetic testing for a TTR mutation.

7. Willingness to return to the treating center for follow-up.

8. Willingness and ability to self-administer, or to have spouse administer weekly subcutaneous injections of study drug.

Exclusion Criteria:

1. Patients who, in the opinion of the Investigator, require further adjustment of diuretics at the time of screening to achieve optimal treatment of heart failure. Once stable for 2 weeks, patients in Class I-III will become eligible for inclusion.

2. Patients with NYHA class 4 congestive heart failure.

3. Concomitant non-amyloid heart disease that might, in the opinion of the investigator, cause changes in strain imaging on serial follow-up (e.g. aortic stenosis of greater than mild severity, unstable coronary artery disease).

4. Prior liver transplantation or liver transplantation anticipated in less than 6 months;

5. ALT and/or AST ³ 2 x ULN and/or Alkaline phosphatase ³ 2 x UNL;

6. Estimated glomerular filtration rate (EGFR) < 50 ml/min;

7. Any other lab values that in the opinion of the investigator might place the subject at unacceptable risk for participation in the study;

8. History of poor compliance with medications or medical treatment, based on a review of medical records.

9. History of hypersensitivity to any of the ingredients of the study therapy;

10. Use of any investigational drug for amyloidosis within 4 weeks prior to study entry or during the study.

11. Current use of tafamidis, diflunisal, doxycycline or TUDCA for therapy of amyloidosis.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Isis 420915/GSK 299872
Open label study in comparison to historic control.

Locations

Country Name City State
n/a

Sponsors (3)

Lead Sponsor Collaborator
Brigham and Women's Hospital GlaxoSmithKline, Ionis Pharmaceuticals, Inc.

Outcome

Type Measure Description Time frame Safety issue
Primary Systolic strain imaging by echocardiographic speckle tracking The primary echocardiographic parameter to be measured will be longitudinal left ventricular (LV) strain (units = % LV longitudinal shortening) as compared to baseline. Month 12 No
Secondary Systolic strain evaluation by echocardiography The primary echocardiographic parameter measured will be longitudinal left ventricular (LV) strain (units = %). Secondary analysis will occur at 18 months No
Secondary Echocardiographic determination of Mean thickness of LV septum and posterior wall (units = mm) 12 months No
Secondary Echocardiographic determination of Mean thickness of LV septum and posterior wall (units = mm) 18 months No
Secondary Echocardiographic determination of LV ejection fraction (units = %) 12 months No
Secondary Echocardiographic determination of LV ejection fraction (units = %) 18 months No
Secondary LV mass measurement by Cardiac MRI (cMRI) (units = grams) 18 months No
Secondary LV cellular component as determined by cMRI (units = % of total LV mass) 12 months No
Secondary LV cellular component as determined by cMRI (units = % of total LV mass) 18 months No
Secondary LV extracellular component as determined by cMRI (units = % of total LV mass) 12 months No
Secondary LV extracellular component as determined by cMRI (units = % of total LV mass) 18 months No
Secondary Extent of cMRI late gadolinium enhancement of the LV (unites = % of area) 12 months No
Secondary Extent of cMRI late gadolinium enhancement of the LV (unites = % of area) 18 months No
Secondary LV mass measurement by Cardiac MRI (cMRI) (units = grams) Month 12 No
See also
  Status Clinical Trial Phase
Recruiting NCT04893889 - Substudy (NCT04456582): Noninvasive Assessment of Myocardial Stiffness by 2D-SWE Ultrasound Technique (Two-dimensional Shear Wave Elastography) in Patients With Amyloidosis and Fabry Disease. N/A
Withdrawn NCT04943302 - Isatuximab and Bendamustine in Systemic Light Chain Amyloidosis Phase 2
Active, not recruiting NCT02909036 - Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant. Phase 1
Completed NCT02816476 - Daratumumab Therapy for Patients With Refractory or Relapsed AL Amyloidosis Phase 2
Completed NCT01083316 - Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis Phase 2
Completed NCT01527032 - Risk-adapted Therapy for Primary Systemic (AL) Amyloidosis Phase 2
Completed NCT02545907 - A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis Phase 1/Phase 2
Recruiting NCT05263817 - A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis Early Phase 1
Active, not recruiting NCT03201965 - A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis Phase 3
Withdrawn NCT02589860 - Analysis of Oral Mucositis in Patient's Undergoing Melphalan Conditioning and Autologous Stem Cell Transplant
Recruiting NCT05635266 - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Completed NCT02574676 - Quality of Life (QOL) Registry for Patients With AL Amyloidosis
Active, not recruiting NCT02260466 - Prevalence and Post-surgical Outcomes of CARdiac Wild-type TransthyrEtin amyloidoSIs in Elderly Patients With Aortic steNosis Referred for Valvular Replacement. N/A
Withdrawn NCT02462213 - Prospective Identification of Cardiac Amyloidosis by Cardiac Magnetic Resonance Imaging N/A
Recruiting NCT05577819 - Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF N/A
Completed NCT01406314 - SAP Depleter Dose Assessment Study in Patients Phase 1
Not yet recruiting NCT04985734 - Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) in Patients With Idiopathic Peripheral Neuropathy N/A
Active, not recruiting NCT03584022 - Clinical Trial to Assess the Safety of a Novel Scaffold Biomaterial N/A
Active, not recruiting NCT05235269 - A Study to Evaluate Organ Level Uptake Repeatability of 124I AT-01 in Subjects With Systemic Amyloidosis Phase 2
Active, not recruiting NCT05199337 - Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis Phase 1/Phase 2